Literature DB >> 28794071

A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib.

Allison M Winter1, Daniel J Landsburg2, Anthony R Mato2, Krista Isaac3, Francisco J Hernandez-Ilizaliturri4, Nishitha Reddy5, Stephen Smith6, Mazyar Shadman6, Mitchell R Smith7, Paolo Caimi8, Deepa Jagadeesh1, Brian T Hill1.   

Abstract

Entities:  

Year:  2017        PMID： 28794071     DOI： 10.1182/blood-2017-05-786988

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  9 in total

1.  Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy.

Authors:  Daniel J Landsburg; Mitchell E Hughes; Alexa Koike; David Bond; Kami J Maddocks; Ling Guo; Allison M Winter; Brian T Hill; Sarah L Ondrejka; Eric D Hsi; Sunita D Nasta; Jakub Svoboda; Stephen J Schuster; Agata M Bogusz
Journal:  Blood Adv       Date:  2019-01-22

Review 2.  Small-Molecule Inhibitors for the Treatment of Diffuse Large B Cell Lymphoma.

Authors:  Joanna Rhodes; Daniel J Landsburg
Journal:  Curr Hematol Malig Rep       Date:  2018-10       Impact factor: 3.952

Review 3.  Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma.

Authors:  P Skrabek; S Assouline; A Christofides; D MacDonald; A Prica; R Sangha; B A Matthews; L H Sehn
Journal:  Curr Oncol       Date:  2019-08-01       Impact factor: 3.677

4.  Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma.

Authors:  Solomon A Graf; Ryan D Cassaday; Karolyn Morris; Jenna M Voutsinas; Qian Vicky Wu; Sanaz Behnia; Ryan C Lynch; Elizabeth Krakow; Heather Rasmussen; Thomas R Chauncey; Sandra Kanan; Lorinda Soma; Stephen D Smith; Ajay K Gopal
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2020-12-03

Review 5.  Genetic Events Inhibiting Apoptosis in Diffuse Large B Cell Lymphoma.

Authors:  Etienne Leveille; Nathalie A Johnson
Journal:  Cancers (Basel)       Date:  2021-04-30       Impact factor: 6.639

6.  Cooperative miRNA-dependent PTEN regulation drives resistance to BTK inhibition in B-cell lymphoid malignancies.

Authors:  Isha Kapoor; Juraj Bodo; Brian T Hill; Alexandru Almasan
Journal:  Cell Death Dis       Date:  2021-11-08       Impact factor: 8.469

7.  Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma.

Authors:  Alex F Herrera; Andre Goy; Amitkumar Mehta; Radhakrishnan Ramchandren; John M Pagel; Jakub Svoboda; Shanhong Guan; John S Hill; Kevin Kwei; Emily A Liu; Tycel Phillips
Journal:  Am J Hematol       Date:  2019-11-06       Impact factor: 10.047

Review 8.  Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma.

Authors:  John Apostolidis; Ayman Sayyed; Mohammed Darweesh; Panayotis Kaloyannidis; Hani Al Hashmi
Journal:  J Immunol Res       Date:  2020-10-29       Impact factor: 4.818

9.  The Basic Research of the Combinatorial Therapy of ABT-199 and Homoharringtonine on Acute Myeloid Leukemia.

Authors:  Yuanfei Shi; Jing Ye; Ying Yang; Yanchun Zhao; Huafei Shen; Xiujin Ye; Wanzhuo Xie
Journal:  Front Oncol       Date:  2021-07-14       Impact factor: 6.244
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.